Author

R. Razafimanantsoa

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Antibody-mediated functional responses induced by the SchistoShield® schistosomiasis vaccine in disease-naïve and endemic human populations.

Schistosomiasis (bilharzia) is a neglected tropical disease caused by Schistosoma spp. Clinical manifestation of chronic schistosomiasis include but not restricted to anemia, growth stunting, hepatosplenomegaly, cognitive impairment in children and male/female genital schistosomiasis. Praziquantel (PZQ) remains the pri...

Aravindan Kalyanasundaram, Desalegn W. Kifle, Jenny N. Davis et al. · Vaccine · 0 citations

Review Open access Aug 2026

Estimating Economic Burden of Schistosomiasis in Madagascar and Burkina Faso

Introduction Schistosomiasis is one of the most pervasive neglected tropical diseases in sub-Saharan Africa as an acute and chronic disease. It presents significant public health challenges in both Madagascar and Burkina Faso. Though schistosomiasis is a high prevalence disease, the understanding of its economic burden...

Y. Hwang, J.-S. Lee, N. Rakotozandrindrainy et al. · medRxiv · 0 citations

Open access Jul 2026

Cost-effectiveness analysis of a hypothetical vaccine for schistosomiasis in Madagascar and Burkina Faso.

Schistosomiasis vaccination has the potential to be a cost-effective intervention, although its economic value depends strongly on vaccine characteristics, implementation costs, and the target population.

Y. Hwang, G. E. Cakpo, N. Rakotozandrindrainy et al. · Vaccine · 0 citations